CA-MFA
7.9.2022 14:01:51 CEST | Business Wire | Press release
MFA, the industry Alliance supporting private network adoption, today announced that it is launching a new resource center on its website for enterprises to gain access to tools that will aid their 3GPP-based private network deployments and to highlight private networks globally. Enterprises can access these tools to simplify their own private network deployments and to learn about available spectrum options in their region.
“The connectivity requirements of enterprises are becoming more complex, with thousands of devices on a network conducting business-critical applications,” said Mazen Chmaytelli, president, MFA. “MFA is a leading industry resource for enterprises looking to understand the benefits and opportunities of 3GPP-based private networks for their business. Our mission is to make it as easy as possible for enterprises to deploy their own private network in any spectrum, and we are providing the tools and resources to help them facilitate that and achieve their digitalization goals.”
As part of its new private networks resource center, MFA is launching a private network tracker in partnership with industry analyst firm, Mobile Experts. The tracker provides insight into the state of private networks across various industry verticals and enterprises as well as regions where private networks are gaining ground.
“As of the end of June 2022, Mobile Experts estimates that more than 2,800 private LTE and 5G networks have been cumulatively deployed,” said Kyung Mun, principal analyst, Mobile Experts. “We also forecast that the private cellular equipment market will grow 12-15% this year to $1.9B and continue to ramp as the industrial device ecosystem scales. We also see that additional regulators are taking their cue from early actions in Germany, Japan, USA and the UK to make available dedicated private 5G spectrum. MFA will be providing ongoing updates on private network deployments globally so enterprises can learn about trends and best practices.”
New monthly newsletter
Enterprises are encouraged to subscribe to MFA’s new newsletter that will feature a monthly update on private networks deployed globally in a variety of industries, as well as feature new white papers, case studies, and resources. Subscribe at www.mfa-tech.org/newsletter.
Uni5G Technology Blueprints available for enterprises
MFA has also made its Uni5G™ Technology Blueprints publicly available for any enterprise to download. The blueprints leverage 3GPP 5G standards to define profiling and classification requirements for private networks. Enterprises can use the blueprints as a tool with their vendor of choice to let them know which select features their devices need to implement. The initial set of blueprints is based on 3GPP Release 15, and the next set of blueprints based on Release 16 and beyond are under development.
Meet us at Hannover Messe USA
MFA will be presenting at Hannover Messe USA in the Solutions Theater located in Building 1, Level 3.
- Monday, Sept. 12, 10:30-11:00AM: Practical Tools to Simplify Your Private Network Deployment by Mazen Chmaytelli, MFA President
- Friday, Sept. 16, 11:15-11:45AM: Deploying a Private 5G Network Doesn’t have to be Rocket Science by Asimakis Kokkos, MFA Technical Specification Group Chair
MFA representatives will also showcase technology solutions and resources in Booth #134661. To schedule a meeting with MFA’s private network experts, contact press@mfa-tech.org.
Resources:
- Download Uni5G Technology Blueprints
- White paper: The MFA Shared PLMN-ID – The ideal solution for your private network development
- View the global spectrum map
- Private network deployment tracker
- Subscribe to our newsletter, MFA Insights: Private Networks Report
About MFA
MFA is an industry Alliance supporting private network adoption. We provide resources that simplify the path to optimized, reliable and secure private networks in locally licensed, shared, or unlicensed spectrum. MFA enables the ecosystem with its free Uni5G™ Technology Blueprints and its unique global PLMN-ID program. Uni5G, based on 3GPP specifications, identifies the key 5G features needed for enterprises to successfully deploy their own private network. MFA is a 3GPP Market Representation Partner. Learn more at www.mfa-tech.org.
Become an MFA member
Join MFA as a contributor or an adopter member to participate in working groups, receive complimentary access to MFA’s Private Network Identifier packages, and to augment your company’s marketing activities. Learn more at Join | MFA (mfa-tech.org).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005526/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing23.3.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3 The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2 This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hol
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 05:00:00 CET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
